D. Boral Capital Reaffirms Buy Rating for Omeros (NASDAQ:OMER)

Omeros (NASDAQ:OMER)‘s stock had its “buy” rating reiterated by investment analysts at D. Boral Capital in a research report issued on Thursday,Benzinga reports. They presently have a $36.00 target price on the biopharmaceutical company’s stock. D. Boral Capital’s price target would suggest a potential upside of 188.23% from the stock’s previous close.

Several other equities analysts also recently weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Omeros in a research report on Wednesday, October 8th. HC Wainwright boosted their price objective on shares of Omeros from $20.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday. Needham & Company LLC reissued a “hold” rating on shares of Omeros in a research note on Wednesday, October 15th. Wall Street Zen upgraded shares of Omeros from a “sell” rating to a “hold” rating in a report on Saturday, December 13th. Finally, WBB Securities reiterated a “strong-buy” rating and set a $45.00 price target on shares of Omeros in a report on Wednesday, October 15th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $40.33.

Omeros Stock Down 7.1%

Omeros stock opened at $12.49 on Thursday. The company’s 50-day moving average price is $10.58 and its 200-day moving average price is $6.64. The company has a market cap of $885.54 million, a PE ratio of -6.18 and a beta of 2.38. Omeros has a twelve month low of $2.95 and a twelve month high of $17.65.

Omeros (NASDAQ:OMER) last released its quarterly earnings results on Thursday, November 13th. The biopharmaceutical company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.58) by $0.39. As a group, sell-side analysts expect that Omeros will post -3.09 earnings per share for the current fiscal year.

Institutional Trading of Omeros

Several institutional investors and hedge funds have recently modified their holdings of the stock. Wealth Enhancement Advisory Services LLC grew its stake in Omeros by 9.0% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 31,728 shares of the biopharmaceutical company’s stock worth $545,000 after purchasing an additional 2,631 shares in the last quarter. JPMorgan Chase & Co. increased its position in Omeros by 1,201.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 416,153 shares of the biopharmaceutical company’s stock valued at $1,706,000 after purchasing an additional 384,168 shares during the period. Millennium Management LLC lifted its position in shares of Omeros by 49.1% in the 3rd quarter. Millennium Management LLC now owns 401,814 shares of the biopharmaceutical company’s stock worth $1,647,000 after purchasing an additional 132,393 shares during the period. Brevan Howard Capital Management LP boosted its stake in shares of Omeros by 22.9% during the third quarter. Brevan Howard Capital Management LP now owns 129,393 shares of the biopharmaceutical company’s stock valued at $531,000 after purchasing an additional 24,094 shares in the last quarter. Finally, Two Sigma Investments LP increased its holdings in Omeros by 39.3% during the third quarter. Two Sigma Investments LP now owns 933,314 shares of the biopharmaceutical company’s stock valued at $3,827,000 after buying an additional 263,095 shares during the period. Institutional investors own 48.79% of the company’s stock.

Key Stories Impacting Omeros

Here are the key news stories impacting Omeros this week:

• Positive Sentiment: HC Wainwright sharply raised its price target to $40 and kept a Buy rating, highlighting large upside vs. the current share level — this upgrade is a clear bullish catalyst. HC Wainwright PT raise
• Positive Sentiment: D. Boral Capital reaffirmed a Buy rating with a $36 price target, providing additional analyst support for upside. D. Boral Capital reaffirmation
• Positive Sentiment: Omeros announced pricing for YARTEMLEA at $36,000 per single‑dose vial — a premium price that boosts near‑term revenue potential for its recently approved transplant complication therapy. Reuters: pricing
• Positive Sentiment: Company comments on FDA approval and commercialization plans for YARTEMLEA underline management’s readiness to commercialize and support uptake, which can validate the higher price target narratives. Seeking Alpha transcript
• Neutral Sentiment: HC Wainwright published detailed near‑term EPS forecasts (Q1–Q4 2026 showing losses) while projecting a large turnaround by FY2030 (EPS $6.69); this signals long‑term optimism but acknowledges multi‑year losses.
• Neutral Sentiment: Needham reiterated a Hold rating, reflecting balanced risk/reward as YARTEMLEA ramps. Needham Hold note
• Neutral Sentiment: There was a reported after‑hours bounce recently, indicating volatile trading around the approval/pricing news rather than steady directional conviction. MSN after‑hours
• Negative Sentiment: Near‑term financials remain loss‑making (consensus and HC Wainwright 2026 EPS estimates are negative), which can pressure the stock until commercial execution and revenue ramp are proven.

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.